📌 Key Takeaways
- A 2026 systematic review in Journal of Cosmetic Dermatology (DOI: 10.1111/jocd.70669)
found that the term “regeneration” is used in aesthetic medicine
without biological precision, requiring urgent conceptual clarification. - “Regeneration,” “repair,” “remodeling,” and “biostimulation”
are distinct biological mechanisms —
most treatments marketed as “regenerative” are more accurately classified as biostimulation. - The core problem is a patient expectation mismatch:
patients who expect tissue to “fully rejuvenate”
may be disappointed when the actual outcome is “collagen production was stimulated.” - Patients have the right to ask:
“What mechanism is at work, to what degree, and for how long?”
before consenting to any so-called regenerative procedure.
“I had regenerative medicine.”
“I received stem cell regeneration therapy.”
“Exosomes boosted my skin’s regenerative capacity.”
These claims are everywhere in aesthetic medicine advertising in 2026.
But a peer-reviewed systematic review published in Journal of Cosmetic Dermatology (Wiley, open access)
has drawn a sharp line:
“The term ‘regeneration’ is being used without biological accuracy,
and conceptual clarification is urgently needed.”
INDEX
Regeneration, Repair, Remodeling, Biostimulation — What’s the Difference?
The 2026 JCD review identifies four distinct biological processes
that are routinely conflated in clinical marketing.
Understanding the difference matters — not just academically, but for informed consent.
Why Misusing the Word “Regeneration” Is a Clinical Problem
Problem ①: Expectation Mismatch — The Root Cause of Patient Disputes
A patient who expects “tissue to rejuvenate through regenerative medicine”
may later discover the procedure was “an injection to stimulate collagen production.”
This gap between expectation and outcome is the underlying cause
of many aesthetic medicine complaints and disputes.
Problem ②: Medical Advertising Compliance Risk
Regulatory bodies in multiple jurisdictions — including Japan’s Ministry of Health, Labour and Welfare —
explicitly prohibit advertising that “emphasizes the efficacy of a procedure
without adequate scientific evidence in order to induce treatment.”
Claims such as “regenerative medicine will transform your skin”
may fall squarely within this prohibition.
Problem ③: Regulatory Ambiguity Around Cell-Based Treatments
When cell therapies (regulated under Japan’s Act on the Safety of Regenerative Medicine)
and non-cell treatments like exosomes or PRP
are all marketed under the same umbrella of “regenerative aesthetics,”
patients lose the ability to determine whether a procedure is legally regulated.
This creates a real risk of undergoing treatments
without verifying whether the clinic holds the required regulatory registration.
The terminology problem is not unique to Japan.
The 2026 JCD review draws on international literature to argue that
the aesthetic medicine industry globally has allowed marketing language
to outpace biological evidence.
Regulatory frameworks in the EU, U.S. (FDA), and South Korea (MFDS)
are each grappling with how to classify and govern
biostimulators, exosomes, and cell-adjacent therapies —
with no unified international standard yet in place.
Three Questions Every Patient Should Ask Before a “Regenerative” Procedure
- “What mechanism is actually at work —
and what specifically changes in my tissue?”
Ask whether collagen is being produced, cells are being activated,
or whether tissue is genuinely being regenerated.
Demand a specific answer. - “Is this procedure subject to regulatory registration
as a cell-based therapy in your jurisdiction?”
In Japan, treatments using living cells require registration
under the Act on the Safety of Regenerative Medicine.
If a clinic cannot provide a registration number, ask why. - “How significant is the effect, and how long does it last?”
The word “regeneration” implies permanence.
A treatment with effects lasting 6 months to 2 years
is a fundamentally different proposition —
and patients deserve to know that distinction upfront.
This is precisely why NERO exists —
to help people choose aesthetic medicine through understanding, not emotion.
When the word “regeneration” shapes a patient’s expectations,
and those expectations go unmet,
the result is not just disappointment — it’s a breakdown of trust.
Accurate language is the foundation of the doctor-patient relationship.
A clinic that says “this is biostimulation” honestly
is, in NERO’s view, the clinic that earns long-term trust.
If you call it “regeneration,”
you should be able to explain what, exactly, is being regenerated.
The precision of language determines the quality of medicine.
Summary
- A 2026 systematic review in Journal of Cosmetic Dermatology found that
“regeneration” is used in aesthetic medicine without biological precision —
and that regeneration, repair, remodeling, and biostimulation are distinct mechanisms. - Most treatments marketed as “regenerative aesthetics” are more accurately classified as
biostimulation.
This does not make them ineffective —
but they deserve to be described with accuracy. - The misuse of terminology creates three compounding problems:
① patient expectation mismatch,
② medical advertising compliance risk,
③ regulatory ambiguity around cell-based treatments. - Patients have the right to ask:
“What mechanism, to what degree, for how long —
and is this procedure registered under applicable regenerative medicine law?”
Frequently Asked Questions
regulated under specific legal frameworks (such as Japan’s Act on the Safety of Regenerative Medicine).
“Regenerative aesthetics” is a broader, less regulated marketing term
that often includes non-cell treatments such as biostimulators and PRP.
If a clinic uses the term “regenerative medicine,”
ask whether they hold the required regulatory registration number.
However, the mechanism, efficacy, and safety profile vary significantly
depending on the type of stem cells used and the delivery method.
In Japan, stem cell treatments require registration under regenerative medicine law.
Treatments at unregistered facilities should be avoided.
they promote repair and remodeling rather than true tissue regeneration.
They do not cause tissue to “fully regenerate” in the biological sense.
Regulatory classification of exosomes remains unsettled in many jurisdictions,
including Japan, the U.S., and South Korea.
Verifying product quality, purity standards, and clinic credentials is essential.
Sources
“Regeneration in Aesthetic Medicine: Mechanisms, Evidence, and Clinical Boundaries” — Journal of Cosmetic Dermatology, 2026 (DOI: 10.1111/jocd.70669, Wiley Periodicals LLC, open access) /
Merenda V et al. “What regenerative means in aesthetic medicine” — Plastic and Aesthetic Research 2026;13:5 (DOI: 10.20517/2347-9264.2025.127) /
Drago L et al. “Regenerative Aesthetics: Present Advances and Emerging Therapies” — Dermatologic Surgery 52(6):548–560, June 2026 (DOI: 10.1097/DSS.0000000000004985) /
Tonnard P, Verpaele A, Romero A. “Clarification of the Concept of Regeneration in the Context of Calcium Hydroxylapatite” — Aesthetic Surgery Journal 2025;sjaf181 (DOI: 10.1093/asj/sjaf181) /
Japan Ministry of Health, Labour and Welfare — Medical Advertising Guidelines (2024 Edition)
